{"id":"cromoglicic-acid","rwe":[{"pmid":"41802283","year":"2026","title":"BioMNEDR: mechanism-guided network embedding for drug repurposing.","finding":"","journal":"Briefings in bioinformatics","studyType":"Clinical Study"},{"pmid":"41075184","year":"2025","title":"Cromolyn as a novel pharmacophore of the Zα domain of the RNA-editing enzyme ADAR1p150.","finding":"","journal":"Protein science : a publication of the Protein Society","studyType":"Clinical Study"},{"pmid":"41064206","year":"2025","title":"CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease - A Bioinformatic Analysis With Clinical Validation.","finding":"","journal":"Health science reports","studyType":"Clinical Study"},{"pmid":"40450750","year":"2025","title":"Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.","finding":"","journal":"Swiss medical weekly","studyType":"Clinical Study"},{"pmid":"37358465","year":"2023","title":"One-Pot Synthesis of Chromone-2-carboxylate Scaffold: An Important Pharmacophore with Diverse Biological Properties.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Mast Cell Stabilizer","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"G-protein coupled receptor 35","category":"target"},{"label":"GPR35","category":"gene"},{"label":"TAS2R20","category":"gene"},{"label":"S100P","category":"gene"},{"label":"A07EB01","category":"atc"},{"label":"Nasal","category":"route"},{"label":"Ophthalmic","category":"route"},{"label":"Respiratory (Inhalation)","category":"route"},{"label":"Inhalant","category":"form"},{"label":"Liquid","category":"form"},{"label":"Solution","category":"form"},{"label":"Solution/ Drops","category":"form"},{"label":"Active","category":"status"},{"label":"Allergic Keratoconjunctivitis","category":"indication"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Asthma","category":"indication"},{"label":"Asthma management","category":"indication"},{"label":"Bronchospasm Prevention","category":"indication"},{"label":"King Pharms","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Allergic Agents","category":"pharmacology"},{"label":"Anti-Asthmatic Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Mast Cell Stabilizers","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":385.262,"date":"","count":225,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 225 times (LLR=385)"},{"llr":99.894,"date":"","count":21,"signal":"Mast cell activation syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=100)"},{"llr":97.501,"date":"","count":19,"signal":"Mastocytosis","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=98)"},{"llr":90.752,"date":"","count":19,"signal":"Perfume sensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=91)"},{"llr":90.152,"date":"","count":63,"signal":"Anaphylactic reaction","source":"DrugCentral FAERS","actionTaken":"Reported 63 times (LLR=90)"},{"llr":68.489,"date":"","count":77,"signal":"Urticaria","source":"DrugCentral FAERS","actionTaken":"Reported 77 times (LLR=68)"},{"llr":50.202,"date":"","count":57,"signal":"Asthma","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=50)"},{"llr":41.406,"date":"","count":9,"signal":"Spleen congestion","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=41)"},{"llr":35.175,"date":"","count":17,"signal":"Food allergy","source":"DrugCentral FAERS","actionTaken":"Reported 17 times (LLR=35)"},{"llr":33.492,"date":"","count":19,"signal":"Skin reaction","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=33)"},{"llr":33.332,"date":"","count":33,"signal":"Angioedema","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=33)"},{"llr":33.081,"date":"","count":71,"signal":"Hypersensitivity","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=33)"},{"llr":31.993,"date":"","count":6,"signal":"Penile erythema","source":"DrugCentral FAERS","actionTaken":"Reported 6 times (LLR=32)"},{"llr":28.477,"date":"","count":11,"signal":"Nasal disorder","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=28)"},{"llr":28.443,"date":"","count":12,"signal":"Mouth swelling","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=28)"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Disease of liver","Hepatic failure","Kidney disease","Nasal polyp"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. In reproductive studies in pregnant mice, rats, and rabbits, cromolyn sodium produced no evidence of fetal malformations at subcutaneous doses up to 540 mg/kg in mice (approximately equal to the maximum recommended daily oral dose in adults on mg/m2 basis) and 164 mg/kg in rats (less than the maximum recommended daily oral dose in adults on mg/m2 basis) or at intravenous doses up to 485 mg/kg in rabbits (approximately times the maximum recommended daily oral dos","Geriatric use":"Clinical studies of Cromolyn Sodium Oral Solution, Concentrate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decrease","Paediatric use":"In adult rats no adverse effects of cromolyn sodium were observed at oral doses up to 6144 mg/kg (approximately 25 times the maximum recommended daily oral dose in adults on mg/m2 basis). In neonatal rats, cromolyn sodium increased mortality at oral doses of 1000 mg/kg or greater (approximately times the maximum recommended daily oral dose in infants on mg"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=cromoglicic acid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:52:42.391256+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cromoglicic Acid","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:52:51.901877+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:52:49.872257+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cromoglicic acid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:52:50.607147+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL428880/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:52:51.742943+00:00"}},"allNames":"intal","offLabel":[],"synonyms":["sodium cromoglicate","cromolyn sodium","sodium cromolyn","sodium cromoglycate","cromoglicic acid","cromoglycic acid","cromolyn","cromoglycate","cromoglicate","intal","cromolyn disodium salt","cromolyn disodium","disodium cromoglycate"],"timeline":[{"date":"1982-05-28","type":"positive","source":"DrugCentral","milestone":"FDA approval (King Pharms)"}],"approvals":[{"date":"1982-05-28","orphan":false,"company":"KING PHARMS","regulator":"FDA"}],"brandName":"Intal","ecosystem":[{"indication":"Allergic Keratoconjunctivitis","otherDrugs":[],"globalPrevalence":null},{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Asthma","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"}],"globalPrevalence":262000000},{"indication":"Asthma management","otherDrugs":[{"name":"beclometasone dipropionate","slug":"beclometasone-dipropionate","company":""},{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"budesonide","slug":"budesonide","company":""},{"name":"ciclesonide","slug":"ciclesonide","company":"Takeda Gmbh"}],"globalPrevalence":262000000},{"indication":"Bronchospasm Prevention","otherDrugs":[{"name":"bitolterol","slug":"bitolterol","company":"Sanofi Aventis Us"},{"name":"levosalbutamol","slug":"levosalbutamol","company":"Oak Pharms Inc"},{"name":"orciprenaline","slug":"orciprenaline","company":""},{"name":"pirbuterol","slug":"pirbuterol","company":""}],"globalPrevalence":null},{"indication":"Giant papillary conjunctivitis","otherDrugs":[],"globalPrevalence":null},{"indication":"Systemic mast cell disease","otherDrugs":[{"name":"avapritinib","slug":"avapritinib","company":"Blueprint Medicines"},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"imatinib","slug":"imatinib","company":"Novartis"},{"name":"rabeprazole","slug":"rabeprazole","company":"Eisai Inc"}],"globalPrevalence":null}],"mechanism":{"target":"G-protein coupled receptor 35","targets":[{"gene":"GPR35","source":"DrugCentral","target":"G-protein coupled receptor 35","protein":"G-protein coupled receptor 35"},{"gene":"TAS2R20","source":"DrugCentral","target":"Taste receptor type 2 member 20","protein":"Taste receptor type 2 member 20"},{"gene":"S100P","source":"DrugCentral","target":"Protein S100-P","protein":"Protein S100-P"}],"modality":"Small Molecule","drugClass":"Mast Cell Stabilizer","explanation":"","oneSentence":"","technicalDetail":"Intal (cromoglicic acid) acts as a mast cell stabilizer by inhibiting the release of histamine and other mediators from mast cells through its interaction with G-protein coupled receptor 35, thereby preventing the activation of the phospholipase C pathway and subsequent degranulation of mast cells."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cromoglicic_acid","title":"Cromoglicic acid","extract":"Cromoglicic acid (INN)—also referred to as cromolyn (USAN), cromoglycate, or cromoglicate—is traditionally described as a mast cell stabilizer, and is commonly marketed as the sodium salt sodium cromoglicate or cromolyn sodium. This drug prevents the release of inflammatory chemicals such as histamine from mast cells.","wiki_history":"==History==\nCromolyn was discovered in 1965 by Roger Altounyan, a pharmacologist who had asthma. Altounyan was investigating certain plants and herbs which have bronchodilating properties. One such plant was khella (Ammi visnaga) which had been used as a muscle relaxant since ancient times in Egypt. Altounyan deliberately inhaled derivatives of the active ingredient khellin to determine if they could block his asthma attacks. After several years of trial, he isolated an effective and safe asthma-preventing compound called cromolyn sodium."},"commercial":{"launchDate":"1982","_launchSource":"DrugCentral (FDA 1982-05-28, KING PHARMS)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/741","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=cromoglicic%20acid","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cromoglicic acid","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cromoglicic_acid","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:19:57.319880","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:53.807972+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"cromoglicic acid","indications":{"approved":[{"name":"Allergic Keratoconjunctivitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA","eligibility":null},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA","eligibility":"Adults and children 3 years of age and older"},{"name":"Asthma","source":"DrugCentral","snomedId":195967001,"regulator":"FDA","eligibility":null,"usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Asthma management","source":"DrugCentral","snomedId":406162001,"regulator":"FDA","eligibility":null,"usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Bronchospasm Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Giant papillary conjunctivitis","source":"DrugCentral","snomedId":231857004,"regulator":"FDA","eligibility":null},{"name":"Systemic mast cell disease","source":"DrugCentral","snomedId":397016004,"regulator":"FDA","eligibility":null},{"name":"Vernal Keratitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":null},{"name":"Vernal conjunctivitis","source":"DrugCentral","snomedId":318316003,"regulator":"FDA","eligibility":null},{"name":"Vernal keratoconjunctivitis","source":"DrugCentral","snomedId":317349009,"regulator":"FDA","prevalenceClass":">1 / 1000","globalPrevalence":12080000,"prevalenceMethod":"orphanet","prevalenceSource":"Orphanet (18356259[PMID])"}],"offLabel":[{"name":"Gastrointestinal food allergy","source":"DrugCentral","drugName":"cromoglicic acid","evidenceCount":30,"evidenceLevel":"moderate"},{"name":"Inflammatory bowel disease","source":"DrugCentral","drugName":"cromoglicic acid"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03794076","phase":"PHASE1,PHASE2","title":"Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia","status":"RECRUITING","sponsor":"Vishwajit Nimgaonkar, MD PhD","startDate":"2019-04-01","conditions":["Schizophrenia","Schizo Affective Disorder"],"enrollment":160,"completionDate":"2028-06"},{"nctId":"NCT07419880","phase":"PHASE2","title":"Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-01-30","conditions":["Triple -Negative Breast Cancer"],"enrollment":46,"completionDate":"2027-04-30"},{"nctId":"NCT07142291","phase":"PHASE2","title":"PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS","status":"RECRUITING","sponsor":"PhenoNet, Inc.","startDate":"2025-11-25","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":105,"completionDate":"2028-03"},{"nctId":"NCT02131038","phase":"","title":"Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2009-05","conditions":["Allergic Rhinitis"],"enrollment":50,"completionDate":"2009-09"},{"nctId":"NCT05076682","phase":"PHASE2","title":"Reverse Triple Negative Immune Resistant Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-06-30","conditions":["Triple-negative Breast Cancer"],"enrollment":80,"completionDate":"2027-03-31"},{"nctId":"NCT06801626","phase":"PHASE3","title":"Novel Strategies for Reducing Burn Scar Itch","status":"RECRUITING","sponsor":"The University of Texas Medical Branch, Galveston","startDate":"2025-03-01","conditions":["Burn Scar","Itch Scarring","Wound"],"enrollment":44,"completionDate":"2027-11-01"},{"nctId":"NCT01722812","phase":"PHASE2","title":"Cromoglicate in Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-11","conditions":["Psoriasis"],"enrollment":30,"completionDate":"2013-05"},{"nctId":"NCT01701843","phase":"PHASE2","title":"Cromoglicate in Mastocytosis","status":"TERMINATED","sponsor":"LEO Pharma","startDate":"2012-10","conditions":["Mastocytosis"],"enrollment":7,"completionDate":"2013-02"},{"nctId":"NCT03167216","phase":"EARLY_PHASE1","title":"Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2017-08-01","conditions":["Chronic Prostatitis With Chronic Pelvic Pain Syndrome"],"enrollment":20,"completionDate":"2022-06-30"},{"nctId":"NCT05077917","phase":"PHASE3","title":"Cromolyn Sodium for Treatment of COVID-19 Pneumonia","status":"TERMINATED","sponsor":"Texas Tech University Health Sciences Center, El Paso","startDate":"2021-11-15","conditions":["COVID-19 Pneumonia","COVID-19 Respiratory Infection","Pneumonia, Viral"],"enrollment":22,"completionDate":"2024-05-23"},{"nctId":"NCT06535087","phase":"","title":"The Impact of Airway Allergic Diseases on Children's and Parents' Quality of Life","status":"RECRUITING","sponsor":"Wenjing Zhou","startDate":"2024-07-20","conditions":["Pediatric Asthma","Rhinitis, Allergic","Quality of Life"],"enrollment":600,"completionDate":"2027-05-31"},{"nctId":"NCT02664051","phase":"PHASE4","title":"Mast Cells in Acid-induced Intestinal Permeability","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2013-08","conditions":["Dyspepsia"],"enrollment":20,"completionDate":"2021-06-29"},{"nctId":"NCT04846348","phase":"PHASE2","title":"Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis","status":"TERMINATED","sponsor":"Joseph Butterfield","startDate":"2021-07-26","conditions":["Cutaneous Mastocytoses"],"enrollment":1,"completionDate":"2021-09-10"},{"nctId":"NCT02371941","phase":"PHASE4","title":"Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis","status":"COMPLETED","sponsor":"University of Tennessee","startDate":"2014-12","conditions":["Eosinophilic Esophagitis"],"enrollment":16,"completionDate":"2017-12"},{"nctId":"NCT04408664","phase":"PHASE3","title":"Influence of Cromones on Eucapnic Hyperventilation (EVH)-Test in Young (Elite) Athletes Who Tested Positive for EIB.","status":"TERMINATED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2021-04-06","conditions":["Exercise-Induced Bronchoconstriction"],"enrollment":8,"completionDate":"2023-08-01"},{"nctId":"NCT04333108","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment","status":"UNKNOWN","sponsor":"AB Science","startDate":"2020-07-01","conditions":["Indolent Systemic Mastocytosis"],"enrollment":140,"completionDate":"2025-06"},{"nctId":"NCT05449444","phase":"PHASE2","title":"Masitinib for the Treatment of Severe Mast Cell Activation Syndrome","status":"UNKNOWN","sponsor":"AB Science","startDate":"2022-07-01","conditions":["Mast Cell Activation Syndrome"],"enrollment":72,"completionDate":"2024-12-31"},{"nctId":"NCT04570644","phase":"PHASE1","title":"Randomized I/II Phase Study of ALZT-OP1 Combination Therapy in Alzheimer's Disease and Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2020-08-28","conditions":["Healthy Volunteers","Alzheimer Disease"],"enrollment":56,"completionDate":"2021-01-18"},{"nctId":"NCT03202147","phase":"PHASE2","title":"Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)","status":"WITHDRAWN","sponsor":"AZTherapies, Inc.","startDate":"2023-12","conditions":["Ischemic Stroke","Post-stroke Cognitive Impairment"],"enrollment":0,"completionDate":"2024-12"},{"nctId":"NCT00777348","phase":"PHASE2","title":"To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2007-11","conditions":["Asthma, Exercise-Induced"],"enrollment":62,"completionDate":"2008-10"},{"nctId":"NCT00943397","phase":"PHASE3","title":"Extended Safety Study of Montelukast in Infants and Young Children With Chronic Asthma (0476-232)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2001-04","conditions":["Asthma"],"enrollment":190,"completionDate":"2001-11"},{"nctId":"NCT02547818","phase":"PHASE3","title":"Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-09-15","conditions":["Alzheimer's Disease"],"enrollment":620,"completionDate":"2020-11-18"},{"nctId":"NCT04428775","phase":"PHASE2","title":"A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease","status":"TERMINATED","sponsor":"AZTherapies, Inc.","startDate":"2020-09-08","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":12,"completionDate":"2021-10-01"},{"nctId":"NCT00814073","phase":"PHASE3","title":"Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis","status":"COMPLETED","sponsor":"AB Science","startDate":"2008-12","conditions":["Indolent Systemic Mastocytosis"],"enrollment":135,"completionDate":"2015-11"},{"nctId":"NCT01933464","phase":"PHASE1,PHASE2","title":"An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2013-08","conditions":["Papulopustular Rosacea"],"enrollment":10,"completionDate":"2014-04"},{"nctId":"NCT01841307","phase":"PHASE1","title":"Cromolyn Detection of Silent Aspiration","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2015-07","conditions":["Gastroesophageal Reflux","Respiratory Aspiration","Idiopathic Pulmonary Fibrosis","Lung Transplantation"],"enrollment":16,"completionDate":"2017-09"},{"nctId":"NCT02566252","phase":"PHASE1","title":"Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)","status":"COMPLETED","sponsor":"Pulmotect, Inc.","startDate":"2015-07","conditions":["Healthy"],"enrollment":16,"completionDate":"2016-03"},{"nctId":"NCT01346852","phase":"","title":"Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":["Asthma"],"enrollment":101437,"completionDate":"2010-04"},{"nctId":"NCT02478957","phase":"PHASE2","title":"Treatment of Indolent Systemic Mastocytosis With PA101","status":"COMPLETED","sponsor":"Patara Pharma","startDate":"2015-06","conditions":["Mastocytosis","Systemic Mastocytosis","Indolent Systemic Mastocytosis"],"enrollment":41,"completionDate":"2016-06"},{"nctId":"NCT02482324","phase":"PHASE1","title":"Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"AZTherapies, Inc.","startDate":"2015-06","conditions":["Healthy Volunteers"],"enrollment":26,"completionDate":"2015-07"},{"nctId":"NCT01175525","phase":"PHASE3","title":"Treatment of Acute Stroke With Cromolyn(Single Dose)","status":"UNKNOWN","sponsor":"Wolfson Medical Center","startDate":"","conditions":["Acute Stroke"],"enrollment":0,"completionDate":""},{"nctId":"NCT00745199","phase":"PHASE2","title":"Evaluating the Effect of Cromolyn Sodium in Uremic Pruritus","status":"COMPLETED","sponsor":"Shiraz University of Medical Sciences","startDate":"2008-05","conditions":["End Stage Renal Disease","Pruritus"],"enrollment":62,"completionDate":"2009-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Nasal, Ophthalmic, Respiratory (Inhalation)","formulation":"Inhalant, Liquid, Solution, Solution/ Drops","formulations":[{"form":"INHALANT","route":"INTRABRONCHIAL","productName":"Cromolyn Sodium"},{"form":"LIQUID","route":"ORAL","productName":"Gastrocrom"},{"form":"SOLUTION","route":"INTRABRONCHIAL","productName":"Cromolyn Sodium"},{"form":"SOLUTION","route":"INTRABRONCHIAL","productName":"Cromolyn Sodium Inhalation"},{"form":"SOLUTION","route":"INTRABRONCHIAL","productName":"Cromolyn Sodium Inhalation Solution"},{"form":"SOLUTION","route":"ORAL","productName":"cromolyn sodium"},{"form":"SOLUTION","route":"RESPIRATORY (INHALATION)","productName":"Cromolyn Sodium Inhalation Solution"},{"form":"SOLUTION, CONCENTRATE","route":"ORAL","productName":"CROMOLYN SODIUM"},{"form":"SOLUTION, CONCENTRATE","route":"ORAL","productName":"Cromolyn Sodium Oral Solution (Concentrate)"},{"form":"SOLUTION/ DROPS","route":"OPHTHALMIC","productName":"Cromolyn Sodium"},{"form":"SPRAY, METERED","route":"NASAL","productName":"Cromolyn Sodium"},{"form":"SPRAY, METERED","route":"NASAL","productName":"NasalCrom"}]},"crossReferences":{"NUI":"N0000147197","MMSL":"159","NDDF":"003422","UNII":"Q2WXR1I0PK","VUID":"4018903","CHEBI":"CHEBI:59773","VANDF":"4018903","INN_ID":"2427","RXNORM":"151906","UMLSCUI":"C0086073","chemblId":"CHEMBL428880","ChEMBL_ID":"CHEMBL428880","KEGG_DRUG":"D00526","DRUGBANK_ID":"DB01003","PUBCHEM_CID":"2882","SNOMEDCT_US":"21701005","IUPHAR_LIGAND_ID":"7608","SECONDARY_CAS_RN":"15826-37-6","MESH_DESCRIPTOR_UI":"D004205"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1982-","companyName":"King Pharms","relationship":"Original Developer"}],"publicationCount":15,"therapeuticAreas":["Respiratory"],"atcClassification":{"source":"DrugCentral","atcCode":"A07EB01","allCodes":["A07EB01","D11AH03","R01AC01","R01AC51","R03AK04","R03AK05","R03BC01","S01GX01","S01GX51"]},"biosimilarFilings":[],"originalDeveloper":"King Pharms","recentPublications":[{"date":"2026 Mar 1","pmid":"41802283","title":"BioMNEDR: mechanism-guided network embedding for drug repurposing.","journal":"Briefings in bioinformatics"},{"date":"2025 Nov","pmid":"41075184","title":"Cromolyn as a novel pharmacophore of the Zα domain of the RNA-editing enzyme ADAR1p150.","journal":"Protein science : a publication of the Protein Society"},{"date":"2025 Oct","pmid":"41064206","title":"CD40LG as a Biomarker in Rheumatoid Arthritis: Links to Bone Destruction and Interstitial Lung Disease - A Bioinformatic Analysis With Clinical Validation.","journal":"Health science reports"},{"date":"2025 Apr 2","pmid":"40450750","title":"Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.","journal":"Swiss medical weekly"},{"date":"2023 Jul 7","pmid":"37358465","title":"One-Pot Synthesis of Chromone-2-carboxylate Scaffold: An Important Pharmacophore with Diverse Biological Properties.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small Molecule","firstApprovalDate":"1982","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-05-28T00:00:00.000Z","mah":"KING PHARMS","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1982-05-28T00:00:00.000Z","mah":"KING PHARMS LLC","brand_name_local":"INTAL","application_number":"NDA018596"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1985-12-05T00:00:00.000Z","mah":"KING PHARMS LLC","brand_name_local":"INTAL","application_number":"NDA018887"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:52:53.807972+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}